当前位置：首页 SCI 期刊医学 Clinical Cancer Research(非官网)

Clinical Cancer ResearchSCIE

国际简称：CLIN CANCER RES 参考译名：临床癌症研究

中科院分区
1区
CiteScore分区
Q1
JCR分区
Q1

基本信息：: ISSN：1078-0432; E-ISSN：1557-3265; 是否OA：未开放; 是否预警：否; TOP期刊：是

出版信息：: 出版地区：UNITED STATES; 出版商：American Association for Cancer Research Inc.; 出版语言：English; 出版周期：Semimonthly; 出版年份：1995; 研究方向：医学-肿瘤学

评价信息：: 影响因子：10; H-index：292; CiteScore指数：20.1; SJR指数：4.623; SNIP指数：1.948

发文数据：: Gold OA文章占比：30.05%; 研究类文章占比：92.93%; 年发文量：467; 自引率：0.0173...; 开源占比：0.1813; 出版撤稿占比：0; 出版国人文章占比：0.05; OA被引用占比：0.0195...

投稿咨询加急见刊

英文简介期刊介绍 CiteScore数据中科院SCI分区 JCR分区发文数据常见问题

英文简介Clinical Cancer Research期刊介绍

Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology, and molecular alterations or biomarkers that predict response or resistance to treatment. The Journal also prioritizes laboratory and animal studies of new drugs and molecule-targeted agents with the potential to lead to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease.

Specific areas of interest include clinical and translational research in targeted therapies; mechanisms of drug sensitivity and resistance; pharmacogenetics and pharmacogenomics; personalized medicine; novel applications of bioinformatics and biostatistics; immunotherapy and clinical immunology; gene therapy; radiobiology and radiation oncology; large-scale molecular characterization of human tumors; diagnostic biomarkers; innovative imaging and other novel methods with potential applicability to clinical investigation; clinical genetics; and detection of minimal disease.

期刊简介Clinical Cancer Research期刊介绍

《Clinical Cancer Research》自1995出版以来，是一本医学优秀杂志。致力于发表原创科学研究结果，并为医学各个领域的原创研究提供一个展示平台，以促进医学领域的的进步。该刊鼓励先进的、清晰的阐述，从广泛的视角提供当前感兴趣的研究主题的新见解，或审查多年来某个重要领域的所有重要发展。该期刊特色在于及时报道医学领域的最新进展和新发现新突破等。该刊近一年未被列入预警期刊名单，目前已被权威数据库SCIE收录，得到了广泛的认可。

该期刊投稿重要关注点：

预计审稿时间：约2.1月
国际TOP期刊
医学
ONCOLOGY
SCIE
中科院1区
非预警

Cite Score数据（2024年最新版）Clinical Cancer Research Cite Score数据

CiteScore：20.1
SJR：4.623
SNIP：1.948

学科类别	分区	排名	百分位
大类：Medicine 小类：Oncology	Q1	21 / 404	94%
大类：Medicine 小类：Cancer Research	Q1	15 / 230	93%

CiteScore 是由Elsevier(爱思唯尔)推出的另一种评价期刊影响力的文献计量指标。反映出一家期刊近期发表论文的年篇均引用次数。CiteScore以Scopus数据库中收集的引文为基础，针对的是前四年发表的论文的引文。CiteScore的意义在于，它可以为学术界提供一种新的、更全面、更客观地评价期刊影响力的方法，而不仅仅是通过影响因子(IF)这一单一指标来评价。

历年Cite Score趋势图

中科院SCI分区Clinical Cancer Research 中科院分区

中科院 2023年12月升级版 综述期刊：否 Top期刊：是

大类学科	分区	小类学科	分区
医学	1区	ONCOLOGY 肿瘤学	1区

中科院分区表 是以客观数据为基础，运用科学计量学方法对国际、国内学术期刊依据影响力进行等级划分的期刊评价标准。它为我国科研、教育机构的管理人员、科研工作者提供了一份评价国际学术期刊影响力的参考数据，得到了全国各地高校、科研机构的广泛认可。

中科院分区表 将所有期刊按照一定指标划分为1区、2区、3区、4区四个层次，类似于“优、良、及格”等。最开始，这个分区只是为了方便图书管理及图书情报领域的研究和期刊评估。之后中科院分区逐步发展成为了一种评价学术期刊质量的重要工具。

历年中科院分区趋势图

JCR分区Clinical Cancer Research JCR分区

2023-2024 年最新版

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q1	27 / 322	91.8%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ONCOLOGY	SCIE	Q1	18 / 322	94.57%

JCR分区的优势在于它可以帮助读者对学术文献质量进行评估。不同学科的文章引用量可能存在较大的差异，此时单独依靠影响因子(IF)评价期刊的质量可能是存在一定问题的。因此，JCR将期刊按照学科门类和影响因子分为不同的分区，这样读者可以根据自己的研究领域和需求选择合适的期刊。

历年影响因子趋势图

发文数据

2023-2024 年国家/地区发文量统计

国家/地区数量
USA2505
England302
Canada301
CHINA MAINLAND289
GERMANY (FED REP GER)263
Spain190
France186
Brazil182
Italy174
Australia151

本刊中国学者近年发表论文

1、Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
Author: Chen, Wei; Shi, Hui; Liu, Zhuojun; Yang, Fan; Liu, Jia; Zhang, Leqiang; Wu, Yajin; Xia, Yuanshi; Ou, Yuxuan; Li, Ruiting; Zhang, Ting; Zhang, Jiecheng; Ke, Xiaoyan; Hu, Kai; Yu, Jian

Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 8, pp. 1484-1495. DOI: 10.1158/1078-0432.CCR-22-2924
2、Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies
Author: Zhai, Yifan; Tang, Qiuqiong; Fang, Douglas D.; Deng, Jing; Zhang, Kaixiang; Wang, Qixin; Yin, Yan; Fu, Chengcheng; Xue, Sheng -Li; Li, Na; Zhou, Feng; Yang, Dajun

Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 1, pp. 183-196. DOI: 10.1158/1078-0432.CCR-22-0978
3、Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer
Author: Peng, Ke; Zhang, Feifei; Wang, Yichen; Sahgal, Pranshu; Li, Tianxia; Zhou, Jin; Liang, Xiaoyan; Zhang, Yanxi; Sethi, Nilay; Liu, Tianshu; Zhang, Haisheng; Bass, Adam J.

Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 1, pp. 197-208. DOI: 10.1158/1078-0432.CCR-22-1609
4、Gene Expression Profiling Identifies Two Chordoma Subtypes Associated with Distinct Molecular Mechanisms and Clinical Outcomes
Author: Bai, Jiwei; Shi, Jianxin; Zhang, Yazhuo; Li, Chuzhong; Xiong, Yujia; Koka, Hela; Wang, Difei; Zhang, Tongwu; Song, Lei; Luo, Wen; Zhu, Bin; Hicks, Belynda; Hutchinson, Amy; Kirk, Erin; Troester, Melissa A.; Li, Mingxuan; Shen, Yutao; Ma, Tianshun; Wang, Junmei; Liu, Xing; Wang, Shuai; Gui, Songbai; McMaster, Mary L.; Chanock, Stephen J.; Parry, Dilys M.; Goldstein, Alisa M.; Yang, Xiaohong R.

Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 1, pp. 261-270. DOI: 10.1158/1078-0432.CCR-22-1865
5、Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
Author: Wang, Jun; Guo, Wei; Wang, Xiaofang; Tang, Xiaodong; Sun, Xin; Ren, Tingting

Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 3, pp. 659-666. DOI: 10.1158/1078-0432.CCR-22-2682
6、Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect
Author: Luo, Ren; Onyshchenko, Kateryna; Wang, Liqun; Gaedicke, Simone; Grosu, Anca-Ligia; Firat, Elke; Niedermann, Gabriele

Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 3, pp. 667-683. DOI: 10.1158/1078-0432.CCR-22-1591
7、First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti-PD-L1 Antibody ZKAB001
Author: Zhou, Yan; Yang, Qingcheng; Dong, Yang; Ji, Tong; Zhang, Bing; Yang, Cheng; Zheng, Shuier; Tang, Lina; Zhou, Chenliang; Qian, Guowei; Huang, Yujing; Yu, Wenxi; Li, Hongtao; Wang, Yonggang; He, Aina; Shen, Zan; Bao, Qiyuan; Hua, Yingqi; Bai, Hongyu; Zhao, Jiayi; Li, Xiaoyi; Dai, Xiangrong; Zhang, Jianjun; Hu, Haiyan; Yao, Yang

Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 4, pp. 764-774. DOI: 10.1158/1078-0432.CCR-22-2470
8、Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Author: Song, Xuyang; Kelley, Robin Kate; Khan, Anis A.; Standifer, Nathan; Zhou, Diansong; Lim, KyoungSoo; Krishna, Rajesh; Liu, Lu; Wang, Kun; McCoon, Patricia; Negro, Alejandra; He, Philip; Gibbs, Megan; Kurland, John F.; Abou-Alfa, Ghassan K.

Journal: CLINICAL CANCER RESEARCH. 2023; Vol. 29, Issue 4, pp. 754-763. DOI: 10.1158/1078-0432.CCR-22-1983